BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population

Pharmacogenetics and Genomics

Volumn 18, Issue 6, 2008, Pages 449-457

  Xu, Ming Qing ^a,b,c,d   St Clair, David ^a   Feng, Guo Yin ^f   Lin, Zhi Guang ^f   He, Guang ^a,c   Li, Xingwang ^a,c   He, Lin ^b,c,e,g  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

^f SHANGHAI MENTAL HEALTH CENTER   (China)

^g Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

Antipsychotics; Association study; Brain derived neurotrophic factor; Chlorpromazine; Clozapine; Extrapyramidal syndrome; Genetic polymorphisms; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CLOZAPINE;

ADULT; AKATHISIA; ALLELE; ARTICLE; BRAIN DERIVED NEUROTROPHIC FACTOR GENE; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG BLOOD LEVEL; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FEMALE; GENE; GENETIC RISK; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE REPEAT; PARKINSONISM; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BASAL GANGLIA DISEASES; BASE SEQUENCE; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; CHINA; CHLORPROMAZINE; DINUCLEOTIDE REPEATS; DNA PRIMERS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SCHIZOPHRENIA; SYNDROME;

EID: 44449172912     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3282f85e26     Document Type: Article

References (44)

1. Joober R, Boksa P, Benkelfat C, Rouleau G. Genetics of schizophrenia: from animal models to clinical studies. J Psychiatry Neurosci 2002; 27:336-347.
2. Strange PG. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 2001; 53:119-133.
3. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112:257-269.
4. Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2003; 8:592-610.
5. Dawson NM, Hamid EH, Egan MF, Meredith GE. Changes in the pattern of brain-derived neurotrophic factor immunoreactivity in the rat brain after acute and subchronic haloperidol treatment. Synapse 2001; 39:70-81.
6. Fumagalli F, Molteni R, Roceri M, Bedogni F, Santero R, Fossati C, et al. Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activity. J Neurosci Res 2003; 72:622-628.
7. Proschel M, Saunders A, Roses AD, Muller CR. Dinucleotide repeat polymorphism at the human gene for the brain-derived neurotrophic factor (BDNF). Hum Mol Genet 1992; 1:353.
8. Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, et al. Characterization of single nucleotide polymorphisms in coding regions of human genes. Nat Genet 1999; 22:231-238.
9. Krebs MO, Guillin O, Bourdell MC, Schwartz JC, Olie JP, Poirier MF, Sokoloff P. Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Mol Psychiatry 2000; 5:558-562.
10. Hawi Z, Straub RE, O'Neill A, Kendler KS, Walsh D, Gill M. No linkage or linkage disequilibrium between brain-derived neurotrophic factor (BDNF) dinucleotide repeat polymorphism and schizophrenia in Irish families. Psychiatry Res 1998; 81:111-116.
11. Virgos C, Martorell L, Valero J, Figuera L, Civeira F, Joven J, et al. Association study of schizophrenia with polymorphisms at six candidate genes. Schizophr Res 2001; 49:65-71.
12. Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF, Weinberger DR. Brainderived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 2003; 23:6690-6694.
13. Ho BC, Milev P, O'Leary DS, Librant A, Andreasen NC, Wassink TH. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch Gen Psychiatry 2006; 63:731-740.
14. Neves-Pereira M, Cheung JK, Pasdar A, Zhang F, Breen G, Yates P, et al. BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol Psychiatry 2005; 10:208-212.
15. Hong CJ, Yu YW, Lin CH, Tsai SJ. An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients. Neurosci Lett 2003; 349:206-208.
16. Liou YJ, Liao DL, Chen JY, Wang YC, Lin CC, Bai YM, et al. Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients. Neuromolecular Med 2004;5:243-251.
17. Numata S, Ueno SI, Iga JI, Yamauchi K, Hongwei S, Ohta K, et al. Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism in schizophrenia is associated with age at onset and symptoms. Neurosci Lett 2007; 401:1-5.
18. Skibinska M, Hauser J, Czerski P, Leszczynska-Rodziewicz A, Kosmowska M, Kapelski P, et al. Association analysis of brain-derived neurotrophic factor (BDNF) gene Val66Met polymorphism in schizophrenia and bipolar affective disorder. World J Biol Psychiatry 2004; 5:215-220.
19. Chen QY, Chen Q, Feng GY, Wan CL, Lindpaintner K, Wang LJ, et al. Association between the brain-derived neurotrophic factor (BDNF) gene and schizophrenia in the Chinese population. Neurosci Lett 2006; 397:285-290. Epub 2006 Jan 9.
20. Kampman O, Anttila S, Illi A, Mattila KM, Rontu R, Leinonen E, Lehtimaki T. Interaction of tumor necrosis alpha-G308A and epidermal growth factor gene polymorphisms in early-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 2005; 255:279-283.
21. Sato T, Bottlender R, Schroter A, Moller HJ. Psychopathology of early-onset versus late-onset schizophrenia revisited: an observation of 473 neuroleptic-naive patients before and after first-admission treatments. Schizophr Res 2004; 67:175-183.
22. Jeste DV, Harris MJ, Krull A, Kuck J, McAdams LA, Heaton R. Clinical and neuropsychological characteristics of patients with late-onset schizophrenia. Am J Psychiatry 1995; 152:722-730.
23. Hafner H, Maurer K, Loffler W, Bustamante S, van der Heiden W, Riecher-Rossler A, et al. Onset and early course of schizophrenia. In: Hafner H, Gattaz WF, editors. Search for the causes of schizophrenia. Berlin-Heidelberg-New York: Springer Verlag; 1995. pp. 43-66.
24. Wu S, Xing Q, Gao R, Li X, Gu N, Feng G, He L. Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett 2005; 376:1-4.
25. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796.
26. Hwang R, Shinkai T, De Luca V, Muller DJ, Ni X, Macciardi F, et al. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology (Berl) 2005; 181:179-187. Epub 2005 Oct 15.
27. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962; 10:799-812.
28. Xu MQ, Xing QH, Zheng YL, Li S, Gao JJ, He G, et al. Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population. J Clin Psychiatry 2007; 68:1358-1367.
29. Lachar D, Bailley SE, Rhoades HM, Varner RV. Use of BPRS-A percent change scores to identify significant clinical improvement: accuracy of treatment response classification in acute psychiatric inpatients. Psychiatry Res 1999; 89:259-268.
30. Kaiser R, Tremblay PB, Klufmoller F, Roots I, Brockmoller J. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia. Mol Psychiatry 2002; 7:695-705.
31. Kores Plesnicar B, Zalar B, Breskvar K, Dolzan V. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. J Psychopharmacol 2006; 20:829-833.
32. Gerlach J, Lublin H, Peacock L. Extrapyramidal symptoms during long-term treatment with antipsychotics: special focus on clozapine and D1 and D2 dopamine antagonists. Neuropsychopharmacology 1996; 14 (3 Suppl):35S-39S.
33. Janno S, Holi MM, Tuisku K, Wahlbeck K. Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population. BMC Neurol 2005; 5:5.
34. Zhao JH. 2LD, Genecounting and HAP: computer programs for linkage disequilibrium analysis. Bioinformatics 2004; 20:1325-1326.
35. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68:978-989.
36. Erdfelder E, Faul F, Buchner A. G*Power: a general power analysis program. Behav Res Methods Instrum Comput 1996; 28:1-11.
37. van Den Bogaert A, Schumacher J, Schulze TG, Otte AC, Ohlruan S, Kovalenko S, et al. The DTNBP1 (dysbindin) gene contributes to schizophrenia, depending on family history of the disease. Am J Hum Genet 2003; 73:1438-1443.
38. Zintzaras E. Brain-derived neurotrophic factor gene polymorphisms and schizophrenia: a meta-analysis. Psychiatr Genet 2007; 17: 69-75.
39. Munafo MR, Thiselton DL, Clark TG, Flint J. Association of the NRG1 gene and schizophrenia: a meta-analysis. Mol Psychiatry 2006; 11: 539-546.
40. Schork NJ, Fallin D, Thiel B, Xu X, Broeckel U, Jacob HJ, Cohen D. The future of genetic case-control studies. Adv Genet 2001; 42 191-212.
41. Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly P; International HapMap Consortium. A haplotype map of the human genome. Nature 2005; 437:1299-1320.
42. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007; 12:707-747.
43. Malaspina D. Schizophrenia: a neurodevelopmental or a neurodegenerative disorder. J Clin Psychiatry 2006; 67:e07.
44. Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001; 411:86-89.